Thus, it seems apparent that despite respiratory problems dominating the clinical symptoms of COVID-19, gastrointestinal problems have been observed in a smaller group of patients (22%), In humans, the most abundant expression of ACE2 occurs in the brush borders of the intestinal enterocytes (Qi et al., 2020), with a recent study demonstrating clinical evidence of the intestine as a target organ for SARS-CoV-2 (Lamers et al., 2020). Here, ACE2 is linked to COVID-19.